替吉奥治疗30例PS=2-3老年晚期胃癌临床观察

Clinical observation of S-1 for 30 patients with elderly advanced gastric cancer in PS=2-3

目的:观察替吉奥胶囊对PS=2-3老年晚期胃癌的治疗疗效及不良反应。方法:采用替吉奥治疗30例PS=2-3老年晚期进展期胃癌患者,对比16例最佳支持治疗患者,化疗2周期后评定疗效,并随访两组患者1年生存状况。结果:治疗组30例中28例可评价疗效和不良反应,治疗组和对照组的近期有效率分别为60.7%和43.8%(P<0.05),1年生存率分别为57.1%和50.0%(P>0.05)。两组PS评分变化无统计学差异,治疗组不良反应轻微,患者能耐受。结论:单药替吉奥方案是疗效较好的治疗PS=2-3老年晚期胃癌的化疗方案,不良反应轻,患者易于耐受。

Objective：To observe the efficacy and toxicity of S-1 for elderly advanced gastric cancer（AGC） in PS=2-3.Methodes： Thirty patients with elderly AGC in PS=2-3 in trial group were evaluated for effect with S-1 after 2 cycles and followed up for 1 year survival status compared with 16 patients in control group.Results： Of 30 patients in trial group,28 were evaluated for effect and safety.The overall response rates were 60.7% and 43.8%（P0.05）,1 year survival rates were 57.1% and 50.0%（P0.05） in trial and control groups,respectively.It was not significant in the improvement rate of PS score between trial and control group,and there was not greatly side reaction in trial group.Conclusion： The oral administration of S-1 is a active regimen and toxicity profile is favourable for elderly AGC in PS=2-3.